Objective: To review the literature on the concomitant use of bisphosphonates and medications that can influence bone metabolism and potentially attenuate bisphosphonate antifracture efficacy. Data Sources: MEDLINE and CINAHL were searched for articles published in English through December 2014 using the following terms: bisphosphonates, bone density conservation agents, acid-suppressive therapy, levothyroxine, thiazolidinediones (TZDs), selective serotonin reuptake inhibitors (SSRIs), bone fractures. Study Selection and Data Extraction: Studies were included if they reported results of concomitant use of any listed medications with bisphosphonates and risk of fractures and focused on women. Articles that focused generally on the use of one of the listed medications and fractures without explicitly examining the potential antifracture efficacy or attenuation of bisphosphonates were excluded. Data Synthesis: A total of 6 relevant studies were identified. Four epidemiological studies reported a statistically significant dose-dependent increase in the risk of fractures when bisphosphonates and acid-suppressive drugs were used together. One post hoc analysis of clinical trial data suggested no attenuation of the antifracture effects of bisphosphonates when used concomitantly with acid-suppressive therapy. One study involving bisphosphonates and SSRIs noted a statistically significant association between fracture risk and SSRI use. No study examining TZDs or levothyroxine with bisphosphonates was identified. Conclusions: Existing research suggests potential attenuation of bisphosphonate antifracture efficacy among patients taking acid-suppressive medications. Based on their pharmacological actions, TZDs, SSRIs, and levothyroxine have similar implications. The paucity of evidence in the literature associating the attenuation of bisphosphonate antifracture efficacy when combined with other medications suggests that further investigation is needed.
GehlbachSHAvruninJSPuleoESpaethR. Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int. 2007;18:805-810.
3.
The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17:25-54.
4.
RouxC. Potential effects of bisphosphonates on bone ultrastructure. Osteoporos Int. 2009;20:1093-1095.
5.
GrahamRRussellG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119:S150-S162.
6.
DavidCConfavreuxCBMehsenN. Severity of osteoporosis: what is the impact of co-morbidities?Joint Bone Spine. 2010;77:S103-S106.
7.
FreidVMBernsteinABBushMA. Multiple Chronic Conditions Among Adults Aged 45 and Over: Trends Over the Past 10 Years. Hyattsville, MD: National Center for Health Statistics; 2012. NCHS Data Brief, No 100.
8.
US Department of Health and Human Services. Multiple Chronic Conditions. A strategic framework: optimum health and Quality of Life for Individuals With Multiple Chronic Conditions. Washington, DC: US Department of Health and Human Services; 2010.
9.
AparasuRBaerRAparasuA. Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm. 2007;3:426-437.
10.
RauchASeitzSBaschantU. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517-531.
11.
YangY-XMetzDC. Reviews in basic and clinical gastroenterology and hepatology. Gastroenterology. 2010;139:1115-1127.
12.
Ing-LorenziniKDesmeulesJPlachtaO. Low-energy femoral fractures associated with long-term use of bisphosphonates. Drug Saf. 2009;32:775-785.
13.
AbrahamsenBEikenPEastellR. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171:998-1004.
14.
O’ConnellMBBorgeltLMBowlesSKVondraceckSF. Drug-induced osteoporosis in the older adult. Aging Health. 2010;6:501-518.
15.
MazziottiGCanalisEGiustinaA. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010;123:877-884.
16.
LeeRHLylesKWColόn-EmericC. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010;8:34-46.
17.
CarboneLDJohnsonKCRobbinsJ. Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the Women’s Health Initiative (WHI). J Bone Miner Res. 2010;25:873-881.
18.
CummingRGLe CouteurDG. Benzodiazepines and risk of hip fractures in older people: a review of evidence. CNS Drugs. 2003;17:825-837.
19.
GaillardSStearnsV. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res. 2011;13:205.
20.
MurphyEGlüerCCReidDM. Thyroid function within the upper normal range is associated with reduced bone mineral density and increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2010;95;3173-3181.
21.
BliziotesMMEshlemanAJZhangXW. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001;29:477-486.
22.
BliziotesMEshlemanABurt-PichatB. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone. 2006;39:1313-1321.
23.
TakedaSElefteriouFLevasseurR. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305-317.
24.
KarsentyG. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 2006;4:341-348.
25.
BruedigamCEijkenMKoedamM. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells. 2010;28:916-927.
26.
LianK-CLangTFKeyakJH. Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naïve postmenopausal women. Osteoporos Int. 2005;16:642-650.
27.
VestergaardPOlsenMLJohnsenSP. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med. 2003;254:486-493.
28.
VestergaardPRejnmarkLMosekildeL. Fracture risk associated with systemic and topical corticosteroids. J Intern Med. 2005;257:374-384.
29.
ManuelS-HDe Tejada-Romero Maria JesusGPedroS-S. Prevalence and risk factors for non-vertebral fractures in patients receiving oral glucocortiocoids. Int J Endocrinol Metab. 2012;10:480-485.
30.
De VriesFPouwelsSLammersJWJ. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med. 2007;261:170-177.
31.
GourlayMFranceschiniNSheynY. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol. 2007;26:144-153.
32.
GrossmanJMGordonRRanganathVK. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-1526.
33.
RizzoliRBodyJJDeCensiAReginsterJYPiscitelliPBrandiML; European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO). Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int. 2012;23:2567-2576.
34.
CascadeEKalaliAHKennedySH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgemont). 2009;6:16-18.
35.
GebaraMASheaMLOLipseyKL. Depression, antidepressants, and bone health in older adults: a systematic review. J Am Geriatr Soc. 2014;62:1434-1441.
36.
KwokCSYeongJK-YLokeYK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48:768-776.
37.
StrampelWEmkeyRCivitelliR. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007;30:755-763.
38.
FrestonJW. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. Am J Med. 2004;117(suppl 5A):14S-22S.
39.
De VriesFCooperALCockleSM. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20:1989-1998.
40.
LeeJYounKChoiNK. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48:1016-1022.
41.
Prieto-AlhambraDPagès-CastellàAWallaceG. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29:268-274.
42.
RouxCGoldsteinJLZhouX. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23:277-284.
43.
ReginsterJMinneHWSorensenOH. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
44.
HarrisSTWattsNBGenantHK. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
45.
McClungMRGeusensPMillerPD. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
46.
AbrahamsenBRubinKHEikenPAEastellR. Characteristics of patients who suffer major osteoporotic fracture despite adhering to alendronate treatment: a National Prescription registry study. Osteoporos Int. 2013;24:321-328.
47.
McMahonADMacDonaldTM. Design issues for drug epidemiology. Br J Clin Pharmacol. 2000;50:419-425.
48.
VestergaardPRejnmarkLMosekildeL. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83.
49.
ItohSSekinoYShinomiyaKTakedaS. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31:206-211.
50.
TurnerMRCamachoXFisherHD. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ. 2011;342:d2238.
51.
ShaneEBurrDEberlingPR. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294.
52.
GiustiAHamdyNATPapapoulosSE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2011;47:169-180.
53.
National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013.
